Drug Database
Back to search

Finland· FI-REL-REL60459

Adempas

A riociguat product containing riociguat, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 17 of our 19 countries.

ATC C02KX05

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedAdempasATCC02KX05REGISTER NO.FI-REL-REL60459PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about riociguatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Riociguat is registered in 17 of 19 countries.

Countries holding a registration under ATC C02KX05 (riociguat), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 10 of them publish a price we can compare per daily dose
Search riociguat products by name

Riociguat · ATC C02KX05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of riociguat costs, country by country.

Normalised to the WHO defined daily dose (4.5 mg), the median price runs from $0.056 in France to $219.06 in Switzerland — a ×3926 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Riociguat · price per daily dose (4.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$219.06
  • IT Italy$147.94
  • FR France$0.056
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Riociguat
Manufacturer
Abacus Medicine A/S
Country
Finland (FI)
ATC code
C02KX05
ATC class
Riociguat
Defined daily dose
4.5 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 2

2 priced
  • fi_myyntilupa
    404275
    84
    EUR 2465
  • fi_myyntilupa
    559917
    42
    EUR 1282.46

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

140 interactions on record for riociguat.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check riociguat against other medicinesHow interaction checks work

Riociguat · interactions on record

140 records

  • 10 severe
  • 103 moderate

Most severe, free to view

  • DipyridamoleB01AC07severe
  • DipyridamolC01DX29severe
  • TheophyllinC01EB28severe
  • KetoconazoleH02CA03severe

27 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Riociguat in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All riociguat products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Austria · Pahrilan
  • Cyprus · Ridecia
  • Greece · Ridecia, Riociguat Win Medica
  • Iceland · Adempas
  • Liechtenstein · Adempas
  • Malta · Midive, Riociguat
  • Netherlands · Pahrilan
  • Norway · Adempas
  • Sweden · Pahrilan, Ridecia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/29f0db1d-0629-41b1-b1ae-ecff47d77722
GET /v1/drugs/29f0db1d-0629-41b1-b1ae-ecff47d77722?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "4.5",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "mg",
  "strength": "2 mg",
  "atc_label": "riosiguaatti",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/13/907/010-011",
  "fimea_rel_id": "REL60459",
  "authorised_at": "2022-08-03"
}
API referenceMCP serverPlans

See everything about riociguat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console